In the 3xTg‐AD mouse model, the HDAC3 inhibitor RGFP‐966 reduces Aβ deposition as well as the phosphorylated tau,14 which might be a secondary effect caused by Aβ.54 This evidence concerns the gene MAPT and Alzheimer disease.